Orbital Therapeutics closes South San Francisco lab, eliminating some roles
Orbital Therapeutics, a well-funded biotech born out of buzzy base editing company Beam Therapeutics, has shuttered its South San Francisco office.
The startup was unveiled in April with a $270 million Series A from ARCH Venture Partners, a16z Bio + Health, and more than half a dozen other investors. The company is working on RNA medicines including vaccines, protein replacement therapies and immunomodulators, with the first expected to enter the clinic within two to four years, CEO Giuseppe Ciaramella told Endpoints News at the time.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.